Gyre Therapeutics, Inc.GYRENASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank97
5Y CAGR+41.2%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+41.2%/yr
Long-term compound
Percentile
P97
Near historical high
vs 5Y Ago
5.6x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 103.77% |
| Q3 2025 | -31.01% |
| Q2 2025 | 10.66% |
| Q1 2025 | -16.62% |
| Q4 2024 | 33.77% |
| Q3 2024 | -17.29% |
| Q2 2024 | 53.76% |
| Q1 2024 | -52.23% |
| Q4 2023 | 51.81% |
| Q3 2023 | -15.67% |
| Q2 2023 | 35.41% |
| Q1 2023 | -57.62% |
| Q4 2022 | -1.03% |
| Q3 2022 | 248.28% |
| Q2 2022 | -81.41% |
| Q1 2022 | -39.86% |
| Q4 2021 | -20.39% |
| Q3 2021 | 32.08% |
| Q2 2021 | -9.81% |
| Q1 2021 | 17.24% |
| Q4 2020 | 18.47% |
| Q3 2020 | -5.09% |
| Q2 2020 | -2.70% |
| Q1 2020 | 22.89% |
| Q4 2019 | 8.72% |
| Q3 2019 | -10.66% |
| Q2 2019 | -7.62% |
| Q1 2019 | 45.98% |
| Q4 2018 | 47.78% |
| Q3 2018 | 43.35% |
| Q2 2018 | 3.13% |
| Q1 2018 | 5.90% |
| Q4 2017 | -6.41% |
| Q3 2017 | 11.88% |
| Q2 2017 | 65.02% |
| Q1 2017 | -33.77% |
| Q4 2016 | -8.36% |
| Q3 2016 | 23.40% |
| Q2 2016 | 20.38% |
| Q1 2016 | 29.45% |